WinHealth Pharma Group and Immedica Pharma AB trategic cooperation on Ravicti®
WinHealth and Immedica enter agreement giving Winhealth rights to Ravicti® in China and several other Asia-Pacific countries. Stockholm, Hangzhou, December 30, 2020 - Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, today announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti® (glycerol phenylbutyrate), in a territory covering the Greater China Area , South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.Ravicti® is in Europe and North America indicated for treatment of ure...
More